About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Diabetes, Obesity and Metabolism
›
Top Articles
Diabetes, Obesity and Metabolism
Endocrinology
6.7
(top 2%)
Impact Factor
7.2
(top 2%)
extended IF
134
(top 2%)
H-Index
3.5K
authors
4K
papers
126.1K
citations
5.6K
citing journals
51.8K
citing authors
Most Cited Articles of Diabetes, Obesity and Metabolism
Title
Year
Citations
Pancreatic beta-cell mass in European subjects with type 2 diabetes
2008
564
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
2007
535
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
2013
501
Adiponectin--a key adipokine in the metabolic syndrome
2006
468
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
2013
460
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c
2010
443
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
2007
437
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
2012
384
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
2013
376
Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
2011
367
Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women
2006
363
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes
2006
360
Insulin-associated weight gain in diabetes--causes, effects and coping strategies
2007
351
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
2012
342
Role of vitamin D in the pathogenesis of type 2 diabetes mellitus
2008
333
Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
2014
321
Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes
2012
303
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
2011
302
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
2015
289
Oxidative stress and potential interventions to reduce oxidative stress in overweight and obesity
2007
289
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
2014
273
Advanced glycation endproducts: what is their relevance to diabetic complications?
2007
272
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
2010
262
Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials
2013
259
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
2011
259
previous
2015
2016
2017
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.